基因疗法增强了脱氧核糖核酶I治疗在抗核氧化酶球体炎中
Anne Cao Le1, Virginie Oudin1, Jonathan Dick1
1Centre for Inflammatory Diseases, Monash University Department of Medicine, Clayton, Victoria, Australia.
JCI insight
|July 9, 2025
概括
细胞外DNA (ecDNA) 在MPO-ANCA GN中驱动脏炎症. 脱氧核糖酶I (DNase I) 疗法,特别是通过基因技术,可以减少炎症和疾病标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
背景情况:
- 死亡细胞中的细胞外DNA (ecDNA) 引发炎症.
- 骨髓氧化酶抗中性粒细胞质抗体相关的质膜炎 (MPO-ANCA GN) 是一种严重的血管炎.
研究的目的:
- 调查ecDNA在MPO-ANCA GN中的作用.
- 评估脱氧核糖核酶I (DNase I) 作为MPO-ANCA GN.GN.的潜在治疗方法.
主要方法:
- 对人类脏活检和小鼠MPO-ANCA GN模型的分析.
- 用静脉注射的DNase I和由腺相关病毒载体输送的DNase I进行治疗.
- 评估淋巴细胞ecDNA,组织学损伤,免疫细胞透,NETosis,T细胞反应和MPO-ANCA标位.
主要成果:
- 在MPO-ANCA GN模型中,DNase I治疗减少了ecDNA沉积,损伤和炎症.
- DNase I调节了树突细胞和MPO特异性T细胞的反应.
- 用DNase I进行基因治疗改善了组织学结果,降低了MPO-ANCA标位,并减少了白蛋白尿.
结论:
- ecDNA是MPO-ANCA GN病原发生的一个关键驱动因素.
- DNase I 是MPO-ANCA GN的一种有前途的治疗剂.
- 基因技术为DNase I输送和MPO-ANCA GN处理提供了一个有效的策略.
更多相关视频
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
8.5K
08:09Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
7.6K
相关概念视频
Gene Therapy
25.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.9K
Myasthenia Gravis: Overview and Treatment
2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Acute Kidney Injury II: Pathophysiology
92
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
92
Acute Kidney Injury I: Introduction
80
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
80
Renal Failure: Dose Adjustments
164
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
164
Nephrotic Syndrome I : Introduction
31
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
31
